This company is also developing a topical anti-androgen (they used to be called Hygeia), and is also doing acne trials first. they will initiate phase 1-2 in 2016, so we're looking at some time before anything comes of it. but for young guys, this is another option in the works for the next decade. Sounds better than CB and also side effect free theoretically. I asked them why they do acne trials first and here is the answer:
Good question. While there appears to be a lot of acne medications, there really hasn't been anything new in a very long time. Mostly reformulations of older drugs.
There are no topical anti androgens on the market for acne and we would be the first. Proof of concept in acne for an anti-androgen opens up the market for other topical anti-androgens. The clinical trials for acne are quicker, and, thus, less expensive, because you'll see regression of an acne lesion in less than 4 weeks. On the contrary, clinical trials for alopecia take significantly longer because of the long growth cycle of hair. So, you can see the decision to see if we have a good anti-androgen signal in the pilosebaceous unit by going after the acne indication first, is an economic one.
I hope this answers your question.
Best,
Yael
Yael Schwartz, Ph.D.
Good question. While there appears to be a lot of acne medications, there really hasn't been anything new in a very long time. Mostly reformulations of older drugs.
There are no topical anti androgens on the market for acne and we would be the first. Proof of concept in acne for an anti-androgen opens up the market for other topical anti-androgens. The clinical trials for acne are quicker, and, thus, less expensive, because you'll see regression of an acne lesion in less than 4 weeks. On the contrary, clinical trials for alopecia take significantly longer because of the long growth cycle of hair. So, you can see the decision to see if we have a good anti-androgen signal in the pilosebaceous unit by going after the acne indication first, is an economic one.
I hope this answers your question.
Best,
Yael
Yael Schwartz, Ph.D.
Comment